LC-MS candidate reference methods for the harmonisation of parathyroid hormone (PTH) measurement: A review of recent developments and future considerations

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 9, 2014, Pages 1251-1263

  Couchman, Lewis ^a,b   Taylor, David R ^a   Krastins, Bryan ^c   Lopez, Mary F ^c   Moniz, Cajetan F ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c Thermo Fisher Scientific   (United States)

Author keywords

Immunoaffinity; Liquid chromatography mass spectrometry (LC MS); Mass spectrometry; Parathyroid hormone (PTH)

Indexed keywords

OXIDIZED PARATHYROID HORMONE; PARATHYROID HORMONE; PEPTIDE; PHOSPHOPROTEIN; PHOSPHORYLATED PARATHYROID HORMONE; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT; PTH PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; CLINICAL CHEMISTRY; CLINICAL LABORATORY; FUTUROLOGY; HISTORICAL RESEARCH; HORMONE DETERMINATION; HUMAN; IMMUNOASSAY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REFERENCE VALUE; REVIEW; TANDEM MASS SPECTROMETRY; BLOOD; BLOOD ANALYSIS; CHEMISTRY; GENETIC VARIABILITY; GENETICS; OXIDATION REDUCTION REACTION; PHOSPHORYLATION; PROCEDURES; TRENDS;

BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, LIQUID; GENETIC VARIATION; HUMANS; IMMUNOASSAY; MASS SPECTROMETRY; OXIDATION-REDUCTION; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEOLYSIS; REFERENCE VALUES;

EID: 84920745938     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0150     Document Type: Review

References (65)

1. Friedman PA. Molecular biology of parathyroid hormone. In: Singh A, Williams G, editors. Textbook of nephro-endocrinology. St Louis: Elsevier Saunders, 2009:95-102.
2. Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJ. PTH - a particularly tricky hormone: why measure it at all in kidney patients. Clin J Am Soc Nephrol 2013;8:299-312.
3. nd ed. London: Elsevier Saunders, 2008:95-107.
4. Pliener-Duxneuner J, Zwettler E, Paschalis E, Roschger P, Nell-Duxeuner V, Klaushofer K. Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int 2009;84:159-70.
5. Mosekilde L, Torring O, Rejnmark L. Emerging anabolic treatments in osteoporosis. Curr Drug Saf 2011;6:62-74.
6. Berson SA, Yalow RS. Immunochemical heterogeneity of parathyroid hormone in plasma. J Clin Endocrinol Metab 1968;28:1037-47.
7. Souberbielle J-C, Friedlander G, Cormier C. Practical considerations in PTH testing. Clin Chim Acta 2005;366:81-9.
8. Bringhurst FR. Circulating forms of parathyroid hormone: peeling back the onion. Clin Chem 2003;49:1973-5.
9. Torres PU. The need for reliable serum parathyroid hormone measurements. Kidney Int 2006;70:240-3.
10. Zhang C-X, Weber B, Thammaving J, Grover TA, Wells DS. Identification of carboxy-terminal peptide fragments of parathyroid hormone in human plasma at low-picomolar levels by mass spectrometry. Anal Chem 2006;78:1636-43.
11. D'Amour P. Circulating PTH molecular forms: what we know and what we don't. Kidney Int 2006;70(Suppl):S29-33.
12. Zimmerman MK, Kumar V, Maine GN, Sykes E. Discrepant intact parathyroid hormone result by immunoassay. Clin Chim Acta 2011;413:344-5.
13. Caron P, Maiza JC, Renaud C, Cormier C, Barres BH, Souberbielle JC. High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/ second generation PTH ratio in patients with primary hyperparathyroidism. Clin Endocrinol 2009;70:533-8.
14. Caron P, Simonds WF, Maiza JC, Rubin M, Cantor T, Rousseau L, et al. Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: a possible link to HRPT2 gene inactivation. Clin Endocrinol 2011;74:694-8.
15. Cavalier E, Daly AF, Betea D, Pruteanu-Apetrii PN, Delanave P, Stubbs P, et al. The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab 2010;95:3745-9.
16. Sturgeon CM, Sprague SM, Metcalfe W. Variation in parathyroid hormone immunoassay results - a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant 2011;26:3440-5.
17. Almond A, Ellis R, Walker SW. Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease. Ann Clin Biochem 2012;49:63-7.
18. Sturgeon CM, Fraser WD, Singh R, Souberbielle JC, Sprague S, Vesper H. Improving the comparability of parathyroid hormone measurements - a report from the IFCC working group for PTH. Biochimica Clinica 2013;37(Suppl):S431.
19. Berson SA, Yalow RS, Aurbach GD, Potts JT. Immunoassay of bovine and human parathyroid hormone. Proc Natl Acad Sci USA 1963;49:613-7.
20. Goodman WG. The evolution of assays for parathyroid hormone. Semin Dial 2005;18:296-301.
21. Blind E, Schmidt-Gayk H, Armbruster FP, Stadler A. Measurement of intact human parathyrin by an extracting two-site immunoradiometric assay. Clin Chem 1987;33:1376-81.
22. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987;33:1364-7.
23. D'Amour P, Brossard J-H, Rousseau L, Roy L, Gao P, Cantor T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003;49: 2037-44.
24. D'Amour P, Brossard JH, Rakel A, Rousseau L, Albert C, Cantor T. Evidence that the amino-terminal composition of non-(1-84) parathyroid hormone fragments starts before position 19. Clin Chem 2005;51:169-76.
25. D'Amour P, Brossard JH, Rousseau L, Nguyen-Yamamoto L, Nassif E, Lazure C, et al. Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 2005;68:998-1007.
26. Blind E, Schmidt-Gayk H, Scharla S, Flentje D, Gohring U, Hitzler W. Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a midregion assay. J Clin Endocrinol Metab 1988;67:353-60.
27. Cohen-Selal ME, Sebert JL, Boudailliez B, Marie A, Moriniere P, Gueris J, et al. Comparison of intact, midregion and carboxyterminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 1991;73:510-4.
28. Brossard JH, Whittom S, Lepage R, D'Amour P. Carboxyterminal fragments of parathyroid hormone are not secreted preferentially in primary hyperparathyroidism as they are in other hypercalcemic conditions. J Clin Endocrinol Metab 1993;77:413-9.
29. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected in intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996;81:3923-9.
30. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic patients. Clin Chem 1998;44:805-9.
31. Divieti P, John MR, Juppner H, Bringhurst FR. Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 2002;143:171-6.
32. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992;75:145-50.
33. John MR, Coolman WG, Gao P, Cantor T, Salusky IB, Juppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84:4287-90.
34. Gao P, Scheibel S, D'Amour P, John MR, Rao SD, Schmidt-Gayk H, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605-14.
35. Taniguchi M, Tanaka M, Hamano T, Nakanishi S, Fujii H, Kato H, et al. Comparison between whole and intact parathyroid hormone assays. Ther Apher Dial 2011;15(Suppl):S42-9.
36. Lafferty FW, Hamlin CR, Corrado KR, Arnold A, Shuck JM. Primary hyperparathyroidism with a low-normal, atypical serum parathyroid hormone as shown by discordant immunoassay curves. J Clin Endocrinol Metab 2006;91:3826-9.
37. Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, et al. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 2000;46:697-703.
38. Hocher B, Armbruster FP, Stoeva S, Reichetzeder C, Gron HJ, Lieker I, et al. Measuring parathyroid hormone (PTH) in patients with oxidative stress - do we need a fourth generation parathyroid hormone assay? PLoS One 2012;7;e40242.
39. Rubin MR, Silverberg SJ, D'Amour P, Brossard JH, Rousseau L, Sliney J Jr, et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1-84) is overproduced in parathyroid carcinoma. Clin Chem 2007;53:1470-6.
40. Vogeser M, Seger C. A decade of HPLC-MS/MS in the routine clinical laboratory - goals for further development. Clin Biochem 2008;41:649-62.
41. Rauh M. Steroid measurement with LC-MS/MS in pediatric endocrinology. Mol Cell Endocrinol 2009;301:272-81.
42. Li H, Rose MJ, Tran L, Zhang J, Miranda LP, James CA, et al. Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS. J Pharmacol Toxicol Methods 2009;59:171-80.
43. Chen Z, Caulfield M, McPhaul MJ, Reitz RE, Taylor SW, Clarke NJ. Quantitative insulin analysis using liquid chromatographytandem mass spectrometry in a high-throughput clinical laboratory. Clin Chem 2013;59:1349-56.
44. Kumar V, Barnidge DR, Chen L-S, Twentyman JM, Cradic KW, Grebe SK, et al. Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin Chem 2010;56:306-13.
45. Nedelkov D. Mass spectrometry-based protein assays for in vitro diagnostic testing. Expert Rev Mol Diagn 2012;12:235-9.
46. Nedelkov D. Mass spectrometry-based immunoassays for the next phase of clinical applications. Expert Rev Proteomics 2006;3:631-40.
47. Kiernan U, Tubbs KA, Gruber K, Nedelkov D, Niederkofler EE, Williams P, et al. High-throughput protein characterization using mass spectrometric immunoassay. Anal Biochem 2002;301:49-56.
48. Ackerman BL. Understanding the role of immunoaffinity-based mass spectrometry methods for clinical applications. Clin Chem 2012;58:1620-2.
49. Lopez MF, Rezai T, Sarracino DA, Prakash A, Krastins B, Athanas M, et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 2010;56:281-90.
50. Krastins B, Prakash A, Sarracino DA, Nedelkov D, Niederkofler EE, Kiernan UA, et al. Rapid development of sensitive, highthroughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clin Biochem 2013;46:399-410.
51. Couchman L, Taylor DR, Krastins B, Lopez MF, Moniz CF. Mass spectrometric immunoassay for intact parathyroid hormone: correlation with immunoassay and application to clinical samples. Ann Clin Biochem 2013;50(Suppl):S14.
52. Couchman L, Taylor DR, Krastins B, Lopez MF, Moniz CF. MSIASRM assay for parathyroid hormone and vitamin D binding protein: correlation with clinical immunoassay methods and application to clinical samples. Endocrine Abstracts 2013;31:41.
53. Rabbani SA, Kremer R, Bennett HP, Goltzman D. Phosphorylation of parathyroid hormone by human and bovine parathyroid glands. J Biol Chem 1984;259:2949-55.
54. Pan C, Valente JJ, Lobrutto R, Pickett JS, Motto M. Combined application of high resolution and tandem mass spectrometers to characterize methionine oxidation in a parathyroid hormone formulation. J Pharm Sci 2010;99:1169-79.
55. Chu J-W, Yin J, Brooks BR, Wang DI, Ricci MS, Brems DN, et al. A comprehensive picture of non-site specific oxidation of methionine residues by peroxides in protein pharmaceuticals. J Pharm Sci 2004;93:3096-102.
56. Tashjian AH, Munson PL, Ontjes DA. Alkylation and oxidation of methionine in bovine parathyroid hormone - effects on hormonal activity and antigenicity. Biochem 1964;3:1175-82.
57. Galceran T, Lewis-Finch J, Martin KJ, Slatopolsky E. Absence of biological effects of oxidized parathyroid hormone-(1-34) in dogs and rats. Endocrinology 1984;115:2375-8.
58. Horiuchi N. Effects of oxidation of human parathyroid hormone on its biological activity in continuously infused, thyroparathy-roidectomized rats. J Bone Miner Res 1988;3:353-8.
59. Zull JE, Smith SK, Wiltshire R. Effect of methionine oxidation and deleted amino-terminal residues on the conformation of parathyroid hormone. Circular dichroism studies. J Biol Chem 1990;265:5671-6.
60. Nabuchi Y, Fujiwara E, Ueno K, Kuboniwa H, Asoh Y, Ushio H. Oxidation of recombinant human parathyroid hormone: effect of oxidized position on the biological activity. Pharm Res 1995;12:2049-52.
61. Hocher B, Oberthur D, Slowinski T, Querfeld U, Schaefer F, Doyon A, et al. Modeling of oxidized PTH (oxPTH) and nonoxidized PTH (n-oxPTH) receptor binding and relationship of oxidized to non-oxidized PTH in children with chronic renal failure, adult patients on hemodialysis and kidney transplant recipients. Kidney Blood Press Res 2013;37:240-51.
62. Zahradnik RJ, Lavigne JR. Assay for the detection of phosphorylated PTH. US Patent Number 8,012,694, B2 2011.
63. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D'Amour P. Synthetic carboxy-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 2001;142:1386-92.
64. D'Amour P. Acute and chronic regulation of circulating PTH: significance in health and in disease. Clin Biochem 2012;45:964-9.
65. Cantor T. The opposing actions of the two parathyroid hormones, 1-84 PTH and 7-84 PTH: improvement in renal bone and calcium metabolism management. Hemodial Int 2004;8:372-85.